Medicine & Life Sciences
Precursor Cell Lymphoblastic Leukemia-Lymphoma
100%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
96%
Acute Myeloid Leukemia
95%
Protein-Tyrosine Kinases
73%
Myelodysplastic Syndromes
59%
Imatinib Mesylate
56%
Leukemia, Myeloid, Chronic Phase
45%
Philadelphia Chromosome
45%
Survival
42%
venetoclax
41%
Inotuzumab Ozogamicin
41%
Dasatinib
36%
Therapeutics
36%
blinatumomab
30%
ponatinib
29%
Cytarabine
27%
Cytogenetics
27%
Decitabine
27%
Mutation
26%
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
26%
Allogeneic Cells
25%
Stem Cell Transplantation
24%
Leukemia
24%
Drug Therapy
24%
Azacitidine
20%
Leukemia, Myelomonocytic, Chronic
15%
Clofarabine
14%
Blast Crisis
14%
Recurrence
13%
Neoplasms
12%
Progression-Free Survival
12%
GATA2 Deficiency
11%
Residual Neoplasm
11%
Bone Marrow
11%
Survival Rate
11%
Vincristine
11%
Safety
11%
Primary Myelofibrosis
10%
fludarabine
10%
Idarubicin
10%
Transplants
10%
B-Lymphocytes
10%
Cyclophosphamide
9%
INCB018424
9%
Phosphotransferases
8%
Salvage Therapy
8%
Hematopoietic Stem Cell Transplantation
8%
Hematologic Neoplasms
8%
Dexamethasone
8%
Gemtuzumab
7%